Standalone H1 FY27: revenue up 42%, PAT up 81%; clean limited review
BIOPOL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the standalone half year ended 30 September 2026, revenue was Rs 4,509.47 lakh, up 42.5% from Rs 3,165.73 lakh a year earlier, and profit after tax was Rs 530.62 lakh, up 80.8% from Rs 293.42 lakh. No consolidated or separate quarterly figures were provided. Net operating cash flow was positive Rs 536.96 lakh, versus negative Rs 196.64 lakh, and the review found no material misstatement.
H1 growth and stronger operating cash flow are positive for shares, but short-term debt rose sharply and cash fell to Rs 10.48 lakh, keeping liquidity in focus.
| Q2 FY27 | Year ago | Change | |
|---|---|---|---|
| Revenue | ₹45.09 Cr | — | — |
| Operating profit | ₹7.07 Cr | — | — |
| Profit after tax | — | — | — |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income. No year-ago figures on this basis yet, so no comparison.